Lifeward Launches Pilot Program With Ottobock Care

HUDSON, Massachusetts & YOKNEAM ILLIT, Israel—Lifeward Ltd., a biomedical company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, launched a pilot program with Ottobock Care, an orthotics and prosthetics patient care organization in the United States. The company said the six-month pilot is designed to enable greater patient access to the ReWalk 7 Personal Exoskeleton.

“Working with Ottobock Care represents an important step in our strategy to make ReWalk available to more people through highly experienced patient care organizations,” said Mark Grant, president and CEO of Lifeward. “Ottobock Care brings the clinical expertise, regional presence and patient support capabilities needed to accelerate access across the U.S. This pilot is designed to establish a scalable model that could lead to broader national distribution.”

The agreement brings together Lifeward’s personal exoskeleton technology and Ottobock Care’s clinical platform and regional patient care infrastructure. Through the pilot, the companies said they intend to increase awareness of ReWalk 7 among rehabilitation hospitals and spinal cord injury centers, develop regional clinical and reimbursement expertise and build sustainable local support for patient evaluation, training and follow-up.

“For more than 100 years, the Ottobock family of companies has been committed to helping people achieve greater mobility and independence through innovative technology and exceptional patient care,” said Kevin Heidenreich, head of patient services at Ottobock Care. “ReWalk 7 is a compelling addition to the advanced mobility solutions we provide our patients. This pilot gives us the opportunity to deliver cutting-edge technologies alongside exceptional clinical care to promote neuromobility access to more people across the country.”